Granted Patent
B2
US 12,650,433 · App. 17/877,410 · Granted Jun 9, 2026
Detection of symmetrical dimethylarginine
Inventors:
Honghzhi Xie (Falmouth, ME); Sreenivasa Rao Ramisetty (South Portland, ME); Murthy Vsn Yerramilli (Falmouth, ME)
Assignee:
IDEXX LABORATORIES, INC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure generally relates to the detection of symmetrical dimethylarginine (SDMA). More particularly, the disclosure relates to the detection of SDMA using a solid phase. The disclosure provides devices, reagents, kits and methods for detecting symmetrical dimethyl arginine (SDMA) in sample, such as a biological sample from an animal. The method includes detecting the presence or amount of SDMA in the sample by using an immunoassay format, such as a competitive immunoassay. The assay includes the use of antibodies to SDMA that are specific for SDMA and that have less affinity for other arginine derivatives.
Claims (18)
1 . A device for determining symmetrical dimethyl arginine (SDMA) in a sample, comprising: a solid matrix comprising a particle non-diffusively bound thereto, wherein the particle comprises a capture reagent comprising an arginine derivative covalently attached to a protein, wherein the protein is non-covalently coated on the particle, wherein the arginine derivative is not SDMA, and wherein the arginine derivative is selected from the group consisting of asymmetrical dimethylarginine (ADMA), L-arginine, N-methylarginine (MMA), acylated ADMA, acylated L-arginine, and acylated MMA, and wherein the protein is selected from the group consisting of Bovine Serum Albumin (BSA), ovalbumin, Keyhole Limpet Hemocyanin (KLH), and Glucose-6-Phosphate Dehydrogenase (G6PDH).
2 . The device of claim 1 , wherein the protein is G6PDH.
3 . The device of claim 2 , wherein the G6PDH is derived from a eukaryote, a prokaryote, a yeast or recombinant expression.
4 . The device of claim 3 , wherein the solid matrix is a porous matrix.
5 . The device of claim 4 , wherein the solid matrix is arranged in a cartridge or housing.
6 . A method of determining symmetrical dimethyl arginine (SDMA) in a sample, comprising:
(a) contacting the sample with the device of claim 1 and a non-immobilized labeled conjugate comprising an anti-SDMA antibody conjugated to a label;
(c) washing the solid matrix to remove conjugate that is not bound to the solid matrix; and
(d) measuring the amount of the label associated with the solid matrix to determine the presence or amount of SDMA in the sample.
7 . The method of claim 6 , wherein step (a) comprises forming a mixture comprising the sample and the conjugate and the contacting the sample with the device comprises contacting the mixture with the device.
8 . The method of claim 6 , wherein the affinity of the anti-SDMA antibody for the arginine derivative is less than about 25% of the affinity of the antibody for SDMA.
9 . The method of claim 6 , wherein the affinity of the anti-SDMA antibody for the arginine derivative is less than about 10% of the affinity of the antibody for SDMA.
10 . The method of claim 6 , wherein the affinity of the anti-SDMA antibody for the arginine derivative is less than about 5% of the affinity of the antibody for SDMA.
11 . The method of claim 6 , wherein the affinity of the anti-SDMA antibody for the arginine derivative is less than about 1% of the affinity of the antibody for SDMA.
12 . The method of claim 6 , wherein the affinity of the anti-SDMA antibody for the arginine derivative is less than about 0.1% of the affinity of the antibody for SDMA.
13 . The method of claim 6 , wherein the affinity of the anti-SDMA antibody for the arginine derivative is less than about 0.01% of the affinity of the antibody for SDMA.
14 . The method of claim 6 , wherein the affinity of the anti-SDMA antibody for the arginine derivative is less than about 0.001% of the affinity of the antibody for SDMA.
15 . The device of claim 1 , wherein the capture reagent comprises the following structure:
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 27, 2023
From: XIE, HONGZHI; RAMISETTY, SREENIVASA RAO; YERRAMILLI, MURTHY VSN
To: IDEXX LABORATORIES, INC.
Reel/Frame 062516/0443 →
Continuity (4)
Provisional Application
62599117
· Dec 15, 2017
Provisional Application
62574592
· Oct 19, 2017
References Cited (160)
US 3875011A
· Rubenstein et al.
· 1975
[cited by applicant]
US 4485177A
· Siedel et al.
· 1984
[cited by applicant]
US 4578361A
· Siedel et al.
· 1986
[cited by applicant]
US 4686181A
· Dona
· 1987
[cited by applicant]
US 4818703A
· Pizzolante
· 1989
[cited by applicant]
US 5318680A
· Fishman et al.
· 1994
[cited by applicant]
US 5726010A
· Clark
· 1998
[cited by applicant]
US 6358699B1
· Balint et al.
· 2002
[cited by applicant]
US 6455288B1
· Jakobovits et al.
· 2002
[cited by applicant]
US 6699673B2
· Aletta
· 2004
[cited by applicant]
US 6706742B2
· Nanteuil et al.
· 2004
[cited by applicant]
US 6720188B2
· Kaddurah-Daouk et al.
· 2004
[cited by applicant]
US 6736957B1
· Forrow et al.
· 2004
[cited by applicant]
US 7611844B2
· Lin et al.
· 2009
[cited by applicant]
US 8481690B2
· Murthy et al.
· 2013
[cited by applicant]
US 8628936B2
· Turner et al.
· 2014
[cited by applicant]
US 9091684B2
· Yerramilli et al.
· 2015
[cited by applicant]
US 9891223B2
· Beaulieu et al.
· 2018
[cited by applicant]
US 9970927B2
· Yerramilli et al.
· 2018
[cited by applicant]
US 9976959B2
· Takanashi
· 2018
[cited by applicant]
US 20050148029A1
· Buechler et al.
· 2005
[cited by applicant]
US 20060094122A1
· Boeger et al.
· 2006
[cited by applicant]
US 20120129265A1
· Lundin et al.
· 2012
[cited by applicant]
US 20140038203A1
· Arthur et al.
· 2014
[cited by applicant]
US 20220221446A1
· Yerramilli
· 2022
[cited by examiner]
CN 101865911A
· 2010
[cited by applicant]
CN 102628868A
· 2012
[cited by applicant]
CN 101587118A
· 2012
[cited by applicant]
CN 101598727B
· 2012
[cited by applicant]
DE 102005060057A1
· 2007
[cited by applicant]
EP 1666884
· 2006
[cited by applicant]
EP 2612147B1
· 2016
[cited by applicant]
JP 2004279412A
· 2004
[cited by applicant]
JP 2012112785A
· 2012
[cited by applicant]
WO 1991019980A1
· 1991
[cited by applicant]
WO 9634271A1
· 1996
[cited by applicant]
WO 9701097A1
· 1997
[cited by applicant]
WO 9849199
· 1998
[cited by applicant]
WO 200204465A1
· 2002
[cited by applicant]
WO 0204950A2
· 2002
[cited by applicant]
WO 2002014873
· 2002
[cited by applicant]
WO 2004001416A1
· 2003
[cited by applicant]
WO 2004046314
· 2004
[cited by applicant]
WO 2006078813
· 2006
[cited by applicant]
WO 2006078813A2
· 2006
[cited by applicant]
WO 2007074864
· 2007
[cited by applicant]
WO 2007074864A1
· 2007
[cited by applicant]
WO 2012029752A1
· 2012
[cited by applicant]
WO 2016134251A1
· 2016
[cited by applicant]
Chang Hwa Lee, “Estimation of GFR”, The Korean Journal of Internal Medicine, 2012, vol. 83, pp. 455-457.
[cited by applicant]
Stevens, et al., “Assessing Kidney Function—Measured and Estimated Glomerular Filtration Rate” NEJM, 354:2473-2483 (2006).
[cited by applicant]
Jepson et al., “Plasma Asymmetric Dimethylarginine, Symmetric Dimethylarginine, L-Arginine, and Nitrite/Nitrate Concentrations in Cats with Chronic Kidney Disease and Hypertension.” J Vet Intern Med, 22:317-324 (2008).
[cited by applicant]
Immunodiagnostik AG-SDMA ELISA Kit for the Determination of SDMA in Human EDT A-Plasma and Serum—Instructions (2009).
[cited by applicant]
Immunodiagnostik AG-SDMA ELISA Kit for the Determination of SDMA in Human EDT A-Plasma and Serum—Instructions (2012).
[cited by applicant]
Nabity, et al., “Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the Early Detection of Chronic Kidney Disease in Dogs,” J Vet Intern Med. 29(4):1036-44 (2015).
[cited by applicant]
Chapter 5: Concepts. In The Immunoassay Handbook, Wild, D. Ed. Nature Publishing Group: United Kingdom, 2nd Edition, pp. 78-86 (2001 ).
[cited by applicant]
Fleck et al., “Serum concentrations of asymmetric (ADMA) and symmetric (SOMA) dimethylarginine in patients with chronic kidney diseases”, Clinica Chimica Acta, 336:1-12 (2003).
[cited by applicant]
Nabity et al., “Correlation of symmetric dimethylarginine with glomerular filtration rate in dogs with chronic bregressive renal disease,” J Vet Intern Med., May 2013, 27(3):733.
[cited by applicant]
Kielstein et al., “SDMA is an early marker of change in GFR after living-related kidney donation,” Nephrology Dialysis Transplantation, Jul. 2011, pp. 324-328, vol. 26, No. 1.
[cited by applicant]
Cooper, A. J. et al. “Cyclic Forms of the alpha-Keio Acid Analogs of Arginine, Citrulline, Homoarginine, and Homocilrulline,” J. Biol. Chem., Aug. 10, vol. 253, No. 15, pp. 5407-5410 (1978).
[cited by applicant]
Dobashi et al., “An automated analyzer for methylated arginines in rat plasma by high-performance liquid chromatography with post-column fluorescence reaction,” Analyst, vol. 127, pp. 54-59 (2002).
[cited by applicant]
Vanholder et al., “Review on uremic toxins: Classification, concentration, and interindividual variability,” Kidney International, May 1, 2003, pp. 1934-1943, vol. 63.
[cited by applicant]
Greene, TW et al., “Chapter 5—Protection for the Carboxyl Group,” Protective Groups in Organic Synthesis, 3rd Edition, 1999, pp. 369-453.
[cited by applicant]
Greene, TW et al., “Chapter 6—Protection for the Thiel Group,” Protective Groups in Organic Synthesis, 3rd Edition 1999, pp. 454-493.
[cited by applicant]
Greene, TW et al., “Chapter 7—Protection for the Amino Group,” Protective Groups in Organic Synthesis, 3rd Edition, 1999, pp. 494-653.
[cited by applicant]
Koch et al., “Regulation and Prognostic Relevance of Symmetric Dimethylarginine Serum Concentrations in Critical Illness and Sepsis,” Mediators of Inflammation, Jun. 27, 2013, pp. 1-8, vol. 2013.
[cited by applicant]
Levey et al., “Glomerular filtration rate measurements in clinical trials: Modification of Diet in Renal Disease Study 28 3roup and the Diabetes Control and Complications Trial Research Group” Journal of the American So…
[cited by applicant]
MacAllister et al., “Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure,” Nephrology Dialysis Transplantation, Dec. 11, 1996, pp. 2449-2452, vol. 11.
[cited by applicant]
Midttun et al., “High-throughput, low-volume, multianalyte quantification of plasma metabolites related to one-carbon 32 metabolism using HPLC-MS/MS,” Analytical and Bioanalytical Chemistry, Dec. 13, 2012, pp. 2009-2017…
[cited by applicant]
Nabity et al., “Day-to-Day Variation of the Urine Protein: Creatinine Ratio in Female Dogs with Stable Glomerular Proteinuria Caused by X-Linked Hereditary Nephropathy,” J Vet Intern Med., 2007, pp. 425-430, vol. 21.
[cited by applicant]
Perrone et al., “Utility of Radioisotopic Filtration Markers in Chronic Renal Insufficiency: Simultaneous Comparison of 1251-lothalamate, 169Yb-DTPA, 99mTc-DTPA, and Inulin,” Am. J. Kidney Disease, 1990, pp. 224-235, vo…
[cited by applicant]
Duerksen, P.J. et al., “Immobilization of Proteins Via Arginine Residues,” Anal. Biochem., vol. 160, pp. 444-454 (1987).
[cited by applicant]
Ogawa et al., “Metabolism of Ng, NG- and NG, NG-Dimethylarginine in rats,” Arch. Biochem. Biophys., vol. 252, No. 2, pp. 526-537 (1987).
[cited by applicant]
Pettersson et al., “Determination of dimethylated arginines in human plasma by high-performance liquid chromatography,” Journal of Chromatography B, vol. 692, pp. 257-262, (1997).
[cited by applicant]
Pi et al., “Improved method for simultaneous determination of L-arginine and its mono- and dimethylated metabolites in biological samples by high-performance liquid chromatography,” Journal of Chromatography B, vol. 742…
[cited by applicant]
Patch D. et al. Abstract of :High Throughput Immunoassay for Kidney Function Biomarker Symmetric Dimethylarginine {SOMA) Clin Chern (2015) pp. 3-3. XP055487566—Retrieved from the Internet: URL:https://www.acc.org/scienc…
[cited by applicant]
Hall et al., “Comparison of Serum Concentrations of Symmetric Dimethylarginine and Creatinine as Kidney Function Biomarkers in Cats with Chronic Kidney Disease,” J Vet Intern Med (2014), 28:1676-1683.
[cited by applicant]
Opiate 200 Ng (OP2) Chemistry Information Sheet, Aug. 2010, Beckman Coulter Inc.
[cited by applicant]
COCM Chemistry Information Sheet, Aug. 2010, Beckman Coulter Inc.
[cited by applicant]
Emil® 2000 Carbamazepine Chemistry Information Sheet, Sep. 2010, Beckman Coulter Inc.
[cited by applicant]
Emil® 2000 Vancomycin Chemistry Information Sheet, Sep. 2010, Beckman Coulter Inc.
[cited by applicant]
Schwarzenbolz, U. et al., “On the reaction of glyoxal with proteins,” Zeitschrift tor Lebensmitteluntersuchung undrorschung A, vol. 205, pp. 121-124 (1997).
[cited by applicant]
A printout retrieved from http://www.science.uwaterloo.ca/-cchieh/cact/c120/bondel.html on Apr. 23, 2018.
[cited by applicant]
A printout P1709 retrieved from https://www.sigmaaldrich.com/catalog/product/sigma/p1709?1ang =en®ion=US on Apr. 23, 2018.
[cited by applicant]
A printout SIA (succinimidyl iodoacetate) retrieved from https://www.thermofisher.com/order/catalog/product/22349 on Apr. 23, 2018.
[cited by applicant]
Sopio, R. et al., “Reaction of 3-deoxypentosulose with N-methyl- and N, N-dimethylguanidine as model reagents for protein-bound arginine and for creatine,” Z. Lebensm. Unters Forsch. A., vol. 201, pp. 381-386(1995).
[cited by applicant]
Stuhlinger et al., “Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase Inhibitor,” J, Am. Med. Assoc., vol. 287, No. 11, pp. 1420-1426 (2002).
[cited by applicant]
Takahashi, Kenji, “The Reaction of Phenylglyoxal with Arginine Residues in Proteins,” J. Biol. Chem., vol. 243, No. 23, pp. 6171-6179 (1968).
[cited by applicant]
Teerlink et al., “Determination of Arginine, Asymmetric Dimethylarginine, and Symmetric Dimethylarginine in Human Plasma and other Biological Samples by High-Performance Liquid Chromatography,” Anal. Biochem., vol. 303,…
[cited by applicant]
Vishwanathan et al., “Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 748, pp. 157-166 (2000).
[cited by applicant]
Cooke, J.P., “Asymmetrical Dimethyolarginine: The Uber Marker?,” Circulation, vol. 109, pp. 1813-1818 (2004).
[cited by applicant]
Acchione et al. “Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates” Landes Bioscience, vol. 4, No. 3, pp. 362-372, 2012.
[cited by applicant]
Bioconjugation Technical Handbook. ThermoFisher Scientific. COL05005, 2015.
[cited by applicant]
Finco Dr, et al., “Relationship between plasma creatinine concentration and glomerular filtration rate in dogs.” Journal Of Veterinary Pharmacology and Therapeutics 18: 418-421 (1995).
[cited by applicant]
Fliser D, et al., “Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease stud.” Journal of the American Society of Nephrology 16: 2456-2461 (2005).
[cited by applicant]
Shreder, K. Synthetic Haptens as Probes of Antibody Response and Immunorecognition. Methods, 20, pp. 372-379 2000).
[cited by applicant]
Baburaj, K. et al., “HOCGO and DMACGO. Two coumarin derived alpha-dicarbonyls suitable as pH and polarity sensitive fluorescent reporters for proteins that can be targeted at reactive arginines,” Biochim. Biophys. Acta,…
[cited by applicant]
Bode-Boger, S.M. et al., “Elevated L-Arginine/Dimethylarginine Ratio Contributes to Enhanced Systemic NO Production by Dietary L-Arginine in Hypercholesterolemic Rabbits,” Biochem. Biophys. Res. Commun., vol. 219, pp. 5…
[cited by applicant]
Chen et al., “Determination of NG, NG-dimethylarginine in human plasma by high-performance liquid chromatography,” Journal of Chromatography B, vol. 692, pp. 467-471 (1997).
[cited by applicant]
Richard, et al., “Arginine methylation regulates IL-2 gene expression: a role for protein arginine methyltransferase 5 (PRMT5),” Biochem J., 388:379-386 (2005).
[cited by applicant]
Mahler, et al., “Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies,” Arthritis Research & Therapy, 7:19-29 (200…
[cited by applicant]
Brahms, et al., “The C-terminal RG Dipeptide Repeats of the Spliceosomal Sm Proteins D1 and D3 contain Symmetrical Dimethylarginines, Which Form a Major B-cell epitope for Anti-Sm Autoantibodies,” The Journal of Biologi…
[cited by applicant]
Boisvert, et al., “Symmetrical dimethylarginine methylation is required for the localization of SMN in Cajal bodies and pre-mRNA splicing,” The Journal of Cell Biology, 159:957-969 (2002).
[cited by applicant]
Boisvert, Francois-Michel, “A role for arginine methylation in DNA repair,” Dissertation abstracts International, 68:34 (2005).
[cited by applicant]
Bode-Böger, et al., “Symmetrical dimethylarginine: A New combined Parameter for renal Function and extent of Coronary Artery Disease,” Journal of the American Society of Nephrology; 17:1128-1134 (2006).
[cited by applicant]
Schnabel, et al., “Asymmetric Dimethylarginine and the Risk of Cardiovascular events and Death in Patients with Coronary Artery Disease—results from the AtheroGene Study,” Circulation Research 97:1-7(2005).
[cited by applicant]
Böger, Rainer, “Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond,” Annals of Medicine, 38:126-136 (2006).
[cited by applicant]
Schulze, et al., “Determination of a reference value for NG, NG-dimethyl-L-arginine in 500 subjects,” European Journal of Clinical Investigation, 35:622-626 (2005).
[cited by applicant]
Kielstein, et al., “Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis,” Nephrol Dial. Transplant, 21:2446-2451 (2006).
[cited by applicant]
Schulze, et al., “Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay,” Clin. Chem. Lab Med. 42:1377-1383 (2004).
[cited by applicant]
ADMA-ELISA, Enzyme Immunoassay for the quantitative Determination of Endogenous Asymmetric Dimethylarginine (ADMA) in Serum or Plasma, (2007).
[cited by applicant]
SDMA-ELISA, Enzyme Immunoassay for the quantitative Determination of Endogenous Symmetric Dimethylarginine (SDMA) in Serum or Plasma, p. 1-16 (2008).
[cited by applicant]
Liu, et al., “New Procedures for Preparation and Isolation of Conjugates of Proteins and a Synthetic Copolymer of D-Amino Acids and Immunochemical Characterization of Such Conjugates,” Biochemistry 18:690 (1979).
[cited by applicant]
Kitagawa, et al., “Preparation and characterization of Hetero-bifunctional Cross-linking Reagents for Protein Modifications,” Chem. Pharm. Bull. 29:1130-1135 (1981).
[cited by applicant]
Duncan, et al., “A New Reagent Which may be Used to Introduce Sulfhydryl Groups into Proteins, and Its use in the Preparation of Conjugates for Immunoassay,” Anal. Biochem 132:68-73 (1983).
[cited by applicant]
Palmer, et al., “Reduction and Reoxidation of a Critical Disulfide Bond in the Rabbit Antibody Molecule,” J. Biol. Chem 238:2393 (1963).
[cited by applicant]
Bedford, et al., “Arginine Methylation: An Emerging Regulator of Protein Function,” Mol. Cell, 18:263-272 (2005).
[cited by applicant]
Blackwell, et al., “Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma,” Eur J. Clin Invest. 37:364-371 (2007).
[cited by applicant]
Nijveldt, et al., “Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia,” Nephrol Dial. Transplant 18:2542-2550 (2003).
[cited by applicant]
Boisvert, et al., “A Proteomic Analysis of Arginine-Methylated Protein Complexes,” Molecular & Cellular Proteomics, 2:1319-1329 (2003).
[cited by applicant]
Fleck, et al., “Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients,” Kidney International, 59:14-18 (2001).
[cited by applicant]
Biovendor Research and Diagnostic Products: “Enzyme Immunoassay for the Quantitative Determination of Endogenous Symmetric Dimethylarginine (SDMA) in Serum or Plasma”, SDMA ELISA, Instructions for use, p. 1-13 (2008).
[cited by applicant]
Upstate cell signaling solutions, “Certificate of Analysis for Anti-dimethyl-Arginine, symmetric (SYM11),” rabbit polyclonal IgG; downloaded May 24, 2011 from www.millipore.com.
[cited by applicant]
Upstate cell signaling solutions, “Certificate of Analysis for Anti-dimethyl-Arginine, symmetric (SYM10),” rabbit antiserum; downloaded May 24, 2011 from www.millipore.com.
[cited by applicant]
“SDMA (human) ELISA kit,” Enzo Life Sciences, Version 01: Dec. 8, 2009.
[cited by applicant]
Moesgaard, et al., “Effects of breed, gender, exercise and white-coat effect on markers of endothelial function in dogs,” Research in Veterinary Science, 82:409-418 (2007).
[cited by applicant]
Product Information List retrieved from DLD Diagnostika GmbH—Online in Jan. 25, 2011.
[cited by applicant]
Mian, I.S. et al., “Structure, Function and Properties of Antibody Binding Sites,” J. Mol. Biol. 217, pp. 133-15 (1991).
[cited by applicant]
King, “Sensitivity of immunoassays for detecting cross-reactivity of homologous venom proteins of yellow jackets,” J. Allergy Clin. Immunol, 79(1): 113-20 (1987).
[cited by applicant]
Lerner et al., “Monoclonal antibodies to nucleic acid-containing cellular constituents: Probes for molecular biology and autoimmune disease,” Proc. Natl. Acad. Sci. USA., 78(5): 2737-41 (1981).
[cited by applicant]
Fenney et al., “Cytoplasmic Assembly and Nuclear Accumulation of Mature Small Nuclear Ribonucleoprotein Particles,” J Biol Chem, 264(10): 5776-83 (1989).
[cited by applicant]
Xu et al, “The C-terminal domain of coilin interacts with Sm proteins and U snRNPs,” Chromosoma, 114(3): 155-66 2005).
[cited by applicant]
Harlow, E. and Lane, D.P. Chapter 5: Immunization and Chapter 14: Immunoassays. In Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, pp. 53-54, 72-87, and 563-604 (1988).
[cited by applicant]
Goodrow et al., “Strategies for Immunoassay Hapten Design,” in Immunoanalysis of Agrochemicals; Nelson, J., et al.; ACS Symposium Series, vol. 586, Chapter 9, pp. 119-139 (1995).
[cited by applicant]
Honda, et al. “Analysis of sDMA modifications of PIWI proteins,” Methods in Molecular Biology, vol. 1093, pp. 137-148 (2013).
[cited by applicant]
Kaptein, “Thyroid Hormone Metabolism and Thyroid Diseases in Chronic Renal Failure,” Endocrine Reviews, vol. 17, No. 1, pp. 45-63 (1996).
[cited by applicant]
Peterson et al., “Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse,” J. Pharmacal. Exp. Ther., vol. 322, No. 1, pp. 30-39 (2007).
[cited by applicant]
Pravetoni et al., “Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities,” Biochem. Pharmacal., Feb. 15, 2012; vol. 83, No. 4, pp. 543-550, Published online Nov. 15, 2011.
[cited by applicant]
Szurdoki et al., “Important Factors in Hapten Design and Enzyme-Linked Immunosorbent Assay Development,” in Immunoanalysis of Agrochemicals; Nelson, J., et al.; ACS Symposium Series, vol. 586, Chapter 4, pp. 39-63 (1995…
[cited by applicant]
Williams T., “Chronic kidney disease in cats with hyperthyroidism,” Clin Brief Sep. 2015:10-12.
[cited by applicant]
Jepson R. Feline hyperthyroidism and chronic kidney disease. In: Proceedings from the BSAVA Congress; Apr. 9-12, 2015; Birmingham, UK.
[cited by applicant]
Englebienne, “Immune and Receptor Assays in Theory and Practice,” CRC Press, 2000, p. 308.
[cited by applicant]
A printout “Imject® Maleimide-Activated mcKLH” retrieved from https://assets.thermofisher.com /TFS-Assets/LSG/manuals/MAN0011384_1mject_Maleimide_Activ_mcKLH_UG.pdf on Feb. 10, 2021.
[cited by applicant]
A printout “SM(PEG)12 (PEGylated, long-chain SMCC crosslinker)” retrieved from https://www.thermofisher.com/order/catalog/product/22112#/22112 on Feb. 5, 2021.
[cited by applicant]
Veiseh et al. “Chlorotozin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery.” Biomaterials, vol. 21, 2010, pp. 8032-8042.
[cited by applicant]